Etamzilat (etamsylate) ampoules 12.5% 2 ml. №10

Description

Etamzilat ampoules Composition

active substance: 1 ml ethamsylate 125 mg
excipients: sodium sulfite anhydrous (E 221), Trilon B, water for injection.

Etamzilat ampoules Dosage form

Injection.

Pharmacological group

ATC code B02B X01.

Etamzilat ampoules Indications

Prevention and control of hemorrhages in the superficial and internal capillaries of various etiologies, especially if the bleeding is caused by damage to the endothelium, in particular:

prevention and treatment of bleeding during and after surgery in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery
prevention and treatment of capillary bleeding of various etiology and localization: hematuria, metrorrhagia, primary hypermenorrhea, hypermenorrhea in women with intrauterine contraceptives, epistaxis, bleeding of the gums,
neonatology prevention of periventricular bleeding in premature infants.

Contraindications

Hypersensitivity to ethamsylate or to any other ingredient of the drug bronchial asthma thrombosis thromboembolism acute porphyria increased blood clotting bleeding against the background of an overdose of anticoagulants with hemoblastosis (lymphatic and myeloid leukemia, osteosarcoma) in children.

Method of administration and dosage

The drug is administered intravenously (slowly) or intramuscularly.

The daily dose for adults is 10-20 mg / kg of body weight, which is administered in 3-4 doses (in most cases, 1-2 ampoules are administered 3-4 times a day). The daily dose for children is 5-10 mg / kg of body weight.

Surgical interventions: before surgery, 1-2 ampoules are administered intravenously or intramuscularly. During the operation, the content of 1-2 ampoules is administered intravenously, the administration of this dose can be repeated. After the operation, the content of 1-2 ampoules is injected every 6:00 until the risk of bleeding disappears.

Neonatology the drug is administered intramuscularly or intravenously at a dose of 12.5 mg / kg body weight (0.1 ml = 12.5 mg). Treatment must be started within the first 2 hours after birth. The drug is administered every 6:00 for 4 days, up to a total dose of 200 mg / kg.

Etamzilat-Darnitsa can be applied topically (skin graft, tooth extraction) using a sterile gauze pad moistened with the drug.

Adverse Reactions

Vascular disorders: very rarely – thromboembolism, arterial hypotension, decreased tissue perfusion, which recovers on its own after a while.

Neurological disorders: rarely – headache, dizziness, hot flashes, paresthesia of the lower extremities.

Gastrointestinal disorders: nausea, vomiting, diarrhea, epigastric pain.

Endocrine disorders: very rarely – acute porphyria.

From the musculoskeletal system and connective tissue: rarely – back pain.

From the immune system: anaphylactic shock (frequency not established), urticaria, exacerbation of bronchial asthma in patients, itching, rash, a case of angioedema has been described.

Violations at the injection site: itching, redness.

Others: facial redness, fever, bronchospasm.

Overdose

To date, there are known cases of drug overdose. Known side effects may increase.

Treatment is symptomatic.